



Adimab

The power of integration.

Press Release

Michael Feldhaus, Ph.D. to join Adimab, Inc. as Senior Director of Antibody Engineering

Lebanon, NH – July 23, 2007 – Adimab, Inc., a biotech startup developing an integrated yeast-based antibody discovery, maturation and biomanufacturing platform, today announced the appointment of Dr. Michael Feldhaus as Senior Director of Antibody Engineering.

Dr. Feldhaus comes to Adimab after leading the antibody discovery effort at Merrimack Pharmaceuticals in Cambridge, MA. In his position as Director of Protein Engineering at Merrimack he was instrumental in integrating all aspects of antibody discovery, and setting new standards for reducing the time from target to GMP cell line generation.

“We are delighted to have Michael joining our team,” says Adimab co-founder and MIT professor Dane Wittrup. “Michael has a fantastic combination of keen insight, drive, and experience, and is the perfect individual to lead this critical effort for Adimab,” Wittrup further explains.

“The Wittrup/Feldhaus duo has done some remarkable things in antibody discovery in yeast”, says Adimab co-founder and Dartmouth Professor Tillman Gerngross. “We are seeing that remarkable synergy unfold again as we address some of the critical issues in yeast based antibody discovery and library design”, adds Gerngross.

“Having personally experienced the quagmire of intellectual property around antibody discovery and maturation allowed me to fully appreciate what Adimab had established; a unique and technically very elegant solution to a complex problem”, says Dr. Feldhaus. “I am excited to join this team and to work closely with Dane and Tillman to fundamentally change the way we discover antibodies,” he adds.

About Adimab, Inc.

Adimab is changing the discovery, maturation and production of therapeutic human antibodies. By integrating all aspects of antibody discovery and developing sophisticated screening methods, Adimab can rapidly select for high affinity antibodies that also behave well in a formulation and manufacturing context. Our proprietary library design and presentation technology allows us to discover full-length human antibodies with broad epitope coverage and high affinity faster than any current technology. For more information, visit www.adimab.com.

Contact

Errik B. Anderson
VP Operations & Finance
Adimab, Inc.
(603) 727-7107
errik.anderson@adimab.com